Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Mouse (Murine) PIAS3 Anticorps:
anti-Human PIAS3 Anticorps:
anti-Rat (Rattus) PIAS3 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal PIAS3 Primary Antibody pour IHC (p), WB - ABIN1882116
Nojiri, Joh, Miura, Sakata, Nomura, Nakao, Sobue, Ohara, Asai, Ito: ATBF1 enhances the suppression of STAT3 signaling by interaction with PIAS3. dans Biochemical and biophysical research communications 2004
Show all 8 Pubmed References
Human Polyclonal PIAS3 Primary Antibody pour IHC (p), WB - ABIN1882115
Long, Wang, Matsuura, He, Liu: Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3). dans Proceedings of the National Academy of Sciences of the United States of America 2004
Show all 7 Pubmed References
Suppressed Th17 levels correlated with upregulated expression of negative regulatory genes, PIAS3, SHP2, and SOCS3 in CD4 T cells during acute SIV infection.
Results show that PIAS3 levels are reduced in a mouse model of atherosclerotic lesions and that its expression decreases in conjunction with increases in interleukin-6 (Montrer IL6 Anticorps) expression and disease severity. These findings provide evidence that results indicate that PIAS3 is a critical repressor of atherosclerosis progression.
Data indicate that PIAS3 (protein inhibitor of activated STAT3) interaction modulates EKLF (erythroid Kruppel-like factor (Montrer KLF1 Anticorps)) activity in a promoter-dependent and SUMO-independent manner.
PIAS3 suppresses acute graft-versus-host disease by modulating effector T and B cell subsets through inhibition of STAT3 (Montrer STAT3 Anticorps) activation.
These data indicate that tachypacing decreased ATBF1 (Montrer ZFHX3 Anticorps), leading to enhanced STAT3 (Montrer STAT3 Anticorps) DNA-binding activity due to the reduced formation of a binary complex of ATBF1 (Montrer ZFHX3 Anticorps) and PIAS3.
MRL/lpr (Montrer FAS Anticorps) mice have significantly increased expressions of STAT3 (Montrer STAT3 Anticorps) mRNA and protein and decreased expression of mRNA PIAS3 in the kidneys compared with BALB/C mice.
L97A, R99N and R99Q mutations of the PINIT domain (PIAS3(85-272) ) were found to abrogate binding to STAT3 (Montrer STAT3 Anticorps), suggesting that these residues were part of a potential binding surface.
Our results indicate that Pias3-dependent SUMOylation of photoreceptor-specific transcription factors is a common mechanism that controls both rod and cone photoreceptor subtype specification, regulating distinct molecular targets in the two cell types
there is an interaction between Zimp7 (Montrer ZMIZ2 Anticorps) and PIAS (Montrer PIAS1 Anticorps) proteins with higher preference for PIAS3, in androgen receptor (Montrer AR Anticorps)-mediated transcription
results indicate a potential role of PIAS3 as transcriptional modulator of TIF2 (Montrer NCOA2 Anticorps)-mediated signalling
role in inducing SUMO-1 (Montrer SUMO1 Anticorps) modification and transcriptional repression of IRF-1 (Montrer IRF1 Anticorps)
PAI-1 (Montrer SERPINE1 Anticorps) interacted with PIAS3 to regulate Stat3 (Montrer STAT3 Anticorps)-dependent gene expression and miR (Montrer MLXIP Anticorps)-34a was transcriptionally suppressed by Stat3 (Montrer STAT3 Anticorps) to form a positive regulatory loop through Stat3 (Montrer STAT3 Anticorps) signaling in non-small cell lung cancer cells.
Levels of PIAS3 are significantly lower, in contrast with phosphorylation of STAT3 (Montrer STAT3 Anticorps), in women with endometriosis compared to women without endometriosis.
TRIM8 (Montrer TRIM8 Anticorps) activates STAT3 (Montrer STAT3 Anticorps) by suppressing the expression of PIAS3, an inhibitor of STAT3 (Montrer STAT3 Anticorps), most likely through E3-mediated ubiquitination and proteasomal degradation.
Low PIAS3 expression is associated with breast cancer organoid invasiveness.
SHP2 (Montrer PTPN11 Anticorps), SOCS3 (Montrer SOCS3 Anticorps) and PIAS3 levels are reduced in medulloblastomas in vivo and in vitro, of which PIAS3 downregulation is more reversely correlated with STAT3 (Montrer STAT3 Anticorps) activation. In resveratrol-suppressed medulloblastoma cells with STAT3 (Montrer STAT3 Anticorps) downregulation and decreased incidence of STAT3 (Montrer STAT3 Anticorps) nuclear translocation, PIAS3 is upregulated, the SHP2 (Montrer PTPN11 Anticorps) level remains unchanged and SOCS3 (Montrer SOCS3 Anticorps) is downregulated.
The results revealed that although the expression levels of SOCS1 (Montrer SOCS1 Anticorps), SOCS3 (Montrer SOCS3 Anticorps) and, in particular, pSHP2, tend to decrease in the four types of astrocytomas, PIAS3 downregulation is more negatively correlated with STAT3 (Montrer STAT3 Anticorps) activation in the stepwise progress of astrocytomas and would indicate an unfavorable outcome.
3-Formylchromone inhibits proliferation and induces apoptosis of multiple myeloma cells by abrogating STAT3 (Montrer STAT3 Anticorps) signaling through the induction of PIAS3.
PIAS3 may serve as a biomarker for predicting hormone therapy stratification, although it is limited to those breast cancer patients receiving hormone therapy.
Taken together, these results suggest that PIAS3 functions as a positive regulator of HIF-1alpha (Montrer HIF1A Anticorps)-mediated transcription by increasing its protein stability.
PIAS3 suppression may be protective against joint destruction in rheumatoid arthritis by regulating synoviocyte migration, invasion, and activation.
This gene encodes a member of the PIAS
protein inhibitor of activated STAT, 3
, E3 SUMO-protein ligase PIAS3-like
, e3 SUMO-protein ligase PIAS3-like
, E3 SUMO-protein ligase PIAS3
, protein inhibitor of activated STAT protein 3
, zinc finger, MIZ-type containing 5
, potassium channel regulatory protein KChAP
, potassium channel-associated protein